Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma
HemaSphere · 2025-01 · 9 (1)
DOI: 10.1002/hem3.70062 ↗Kurz gefasst
Fachartikel in der Zeitschrift HemaSphere, online erschienen am 13.01.2025. Verfasst von Sophia Stock und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine III LMU University Hospital LMU Munich Munich Germany. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Deutsche Forschungsgemeinschaft, Wilhelm Sander-Stiftung.
Abstract (Originalsprache)
Immune deficits after CD19 chimeric antigen receptor (CAR) T‐cell therapy can be long‐lasting, predisposing patients to infections and non‐relapse mortality. In B‐cell non‐Hodgkin lymphoma (B‐NHL), the prognostic impact of immune reconstitution (IR) remains ill‐defined, and detailed cross‐product comparisons have not been performed to date. In this retrospective observational study, we longitudinally characterized lymphocyte subsets and immunoglobulin levels in 105 B‐NHL patients to assess patterns of immune recovery arising after CD19 CAR‐T. Three key IR criteria were defined as CD4 + T helper (T H ) cells > 200/µL, any detectable B cells, and serum immunoglobulin G (IgG) levels >4 g/L. After a median follow‐up of 24.6 months, 38% of patients displayed T H cells, 11% showed any B cells, and 41% had IgG recovery. Notable product‐specific differences emerged, including deeper T H cell aplasia with CD28z‐ versus longer B‐cell aplasia with 41BBz‐based products. Patients with any IR recovery experienced extended progression‐free survival (PFS) (median 20.8 vs. 1.7 months, p < 0.0001) and overall survival (OS) (34.9 vs. 4.0 months, p < 0.0001). While landmark analysis at 90 days confirmed improved PFS in patients with any recovery (34.9 vs. 8.6 months, p = 0.005), no significant OS difference was noted. Notably, 72% of patients with refractory disease never displayed recovery of any IR criteria. Early progressors showed diminished IR at the time of progression/relapse compared to patients with late progression/recurrence (after Day 90). Our results highlight the profound immune deficits observed after CD19 CAR‐T and shed light on the intersection of IR and efficacy in B‐NHL. Importantly, IR was impaired considerably postprogression, carrying significant implications for subsequent T‐cell‐engaging therapies and treatment sequencing.
Autor:innen und Institutionen
- Department of Medicine III LMU University Hospital LMU Munich Munich Germany.
- Division of Clinical Pharmacology, Department of Medicine IV LMU University Hospital, LMU Munich Munich Germany.
- German Cancer Consortium (DKTK) Partner Site Munich, a partnership between the DKFZ Heidelberg and LMU University Hospital Munich Germany.
- Laboratory for Translational Cancer Immunology, LMU Gene Center Munich Germany.
- Cellular Immunotherapy Program Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown and Broad Institute of Harvard University and Massachusetts Institute of Technology Cambridge Massachus…
- Dana-Farber Cancer Institute Boston Massachusetts USA.
ORCID-Profile: Kai Rejeski
Förderung
- NCI NIH HHS
- Deutsche Forschungsgemeinschaft
- Wilhelm Sander-Stiftung
Zitieren
APA
Stock, S., Bücklein, V. L., Blumenberg, V., Magno, G., Emhardt, A. J., Holzem, A. M. E., Cordas Dos Santos, D. M., Schmidt, C., Grießhammer, S., Frölich, L., Kobold, S., von Bergwelt-Baildon, M., Rejeski, K., & Subklewe, M. (2025). Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma. HemaSphere, 9(1). https://doi.org/10.1002/hem3.70062
Vancouver
Stock S, Bücklein VL, Blumenberg V, Magno G, Emhardt AJ, Holzem AME, et al. Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma. HemaSphere. 2025;9(1). doi:10.1002/hem3.70062
BibTeX
@article{Stock2025,
author = {Stock, Sophia and Bücklein, Veit L and Blumenberg, Viktoria and Magno, Giulia and Emhardt, Alica-Joana and Holzem, Alessandra M E and Cordas Dos Santos, David M and Schmidt, Christian and Grießhammer, Stefanie and Frölich, Lisa and Kobold, Sebastian and von Bergwelt-Baildon, Michael and Rejeski, Kai and Subklewe, Marion},
title = {Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma},
journal = {HemaSphere},
year = {2025},
volume = {9},
number = {1},
doi = {10.1002/hem3.70062}
}
EUVIMED